Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD

Related Clinical Trial
A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals COPD Exacerbation Blood and Urine Biomarkers Study Alpha-1 Carrier Genomics Study Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Study of ARO-AAT in Normal Adult Volunteers Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry Respreeza® Self-administration and Learning Program (AmAREtTI Study) Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Environment Effect on Six-Minute Walk Test Performance Alpha-1 Foundation DNA and Tissue Bank Alpha1-antitrypsin Deficiency Registry Alpha-1 Research Registry Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Alpha-1 Coded Testing(ACT) Study Long-Term Follow-up Study of ADVM-043 Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation” EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency Alpha-1 Foundation Research Registry Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor) Aralast alpha1-proteinase Inhibitor Surveillance Study Pharmacokinetic Study of ARALAST (Human Alpha1- PI) The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Brief Title

Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD

Official Title

A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of "Kamada-AAT for Inhalation" 80 mg Per Day in Adult Patients With Congenital Alpha-1 Antitrypsin Deficiency

Brief Summary

      Alpha-antitrypsin (AAT) is a member of the serpin family of proteinase inhibitors and is to a
      large extent responsible for restricting proteinases, notably neutrophil elastase, and
      proteinase 3, which might otherwise attack the lung tissue. Individuals with a genetic
      deficiency of alpha-1-antitrypsin (AATD) are at a significantly increased risk (80-100%) of
      developing emphysema. This study is designed to administer a solution of AAT by nebulizer so
      that patients can inhale the drug instead of requiring infusions as in current treatment. A
      significant advantage of inhalation is that the AAT is directly transferred to the lungs,
      which is the site most in need of the protein. Previous results show that in addition to the
      added convenience, three times higher concentrations of AAT can be achieved in the lungs by
      inhalation than by intravenous infusions. To date, more than 220 patients have completed
      Inhalation studies for several indications.

      The current study population will consist of adult patients with congenital alpha-1
      antitrypsin (AAT) deficiency who have moderate airflow limitation (forced expiratory volume
      in 1 second 50% ≤ [FEV1] ≤ 80% of predicted) and FEV1/slow vital capacity [SVC] ≤ 70% and who
      have not experienced two or more moderate or one or more severe exacerbations of COPD during
      the past year. A total of 220 patients will be recruited, and after 4 weeks practice inhaling
      saline with the nebulizer, will be randomized 1:1 to inhale either 80 mg/day "Kamada-AAT for
      Inhalation" or a placebo with identical appearance. Patients will be treated for 104 weeks
      and then followed up for a further 26 weeks. Over this time there will be 13 visits to the
      clinical study site for evaluation of lung function by blood tests and CT densitometry. In
      addition the patients will be required to fill out a daily e-diary with details of the
      inhalations and will also report their daily symptoms.

Study Phase

Phase 3

Study Type


Primary Outcome

FEV1 post bronchodilator

Secondary Outcome

 CT densitometry whole-lung 15th percentile lung density (PD15) at total lung capacity (TLC).


Alpha 1-Antitrypsin Deficiency


Alpha 1-Antitrypsin

Study Arms / Comparison Groups

 Inhaled AAT
Description:  Daily inhalation of 80 mg/day "Kamada-AAT for Inhalation" for 104 weeks


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

November 25, 2019

Completion Date

May 2023

Primary Completion Date

November 2022

Eligibility Criteria

        Inclusion Criteria:

          1. Diagnosis of severe AAT deficiency, i.e. patients with either Pi(ZZ), Pi(Z/Null), or
             Pi(Null/Null) genotypes confirmed by genotype blood test documented prior to

          2. Serum AAT levels ≤ 11 µM at screening.

          3. Lung disease with clinical evidence of airflow limitation (post bronchodilator
             FEV1/SVC ≤ 70%) at screening.

          4. 50% ≤ FEV1 ≤ 80% of predicted post-bronchodilator at screening.

          5. Patients who are either naïve or washed out of any AAT treatment (by IV) for at least
             8 weeks prior to randomization.

          6. Age between 18 to 65 years inclusive at screening.

          7. Able to read and sign informed consent and willing to participate in the study.

          8. Males or non-pregnant, non-lactating females whose screening pregnancy test is
             negative, who are using contraceptive methods deemed reliable by the investigator, who
             are post-menopausal, or are surgically sterilized.

          9. High compliance during run in defined as study medication use and e-Diary compliance
             for at least 20 out of the 28 days of run in.

        Exclusion Criteria:

          1. Immunoglobulin A (IgA) absolute deficiency defined as serum IgA levels < 0.05 g/L at

          2. History of life-threatening transfusion reaction(s), allergy, anaphylactic reaction,
             or systemic response to human plasma-derived products.

          3. Two or more moderate or any severe exacerbation(s) within the year prior to the
             baseline visit.

          4. A moderate exacerbation within 6 weeks prior to the baseline.

          5. Use of oral or parenteral glucocorticoids in doses above 10 mg of prednisone daily or
             equivalent generics (substance and dose).

          6. Clinically significant inter-current illnesses (except for respiratory or liver
             disease secondary to AAT deficiency), including: cardiac, hepatic, renal, endocrine,
             neurological, hematological, neoplastic, immunological, skeletal, or other. Patients
             might be included after consultation with the treating physician and the sponsor if,
             in the opinion of the Investigator, their condition will not interfere with the
             safety, compliance or other aspects of this study.

          7. Hospitalization for any cause 6 weeks prior to screening.

          8. History of lung or liver transplant.

          9. On any thoracic or hepatic surgery waiting list.

         10. Any lung surgery within the past two years (including bronchoscopic lung volume

         11. Any smoking within the year prior to screening.

         12. Evidence of alcohol abuse or history of alcohol abuse, or use of illegal drugs and/or
             abuse of legally prescribed drugs in the last 5 years prior to screening.

         13. Acute or chronic hepatitis (hepatitis A, hepatitis B, hepatitis C), and/or positive
             human immunodeficiency virus (HIV) serology.

         14. Signs of significant abnormalities in serum hematology, serum chemistry, serum
             inflammatory / immunogenic markers and urinalysis per investigator judgment, taking
             into considerations the potential effects of the AAT deficiency.

         15. Signs of significant abnormalities in ECG per investigator judgment at screening.

         16. Presence of psychiatric/ mental disorder or any other medical disorder that might
             impair the patient's ability to give informed consent or to comply with the
             requirements of the study protocol. If, in the opinion of the Investigator, the
             condition will not interfere with the compliance or other aspects of this study, the
             patient might be included after consultation with the treating physician and the

         17. Previous exposure to inhaled AAT.

         18. Participation in another clinical trial involving investigational medication or
             interventional treatment within 30 days and/or last dose 5 half-lives prior to
             screening visit.

         19. Inability to attend scheduled clinic visits and/or comply with study protocol.

         20. Any other factor that, in the opinion of the investigator, would prevent the patient
             from complying with the requirements of the protocol.




18 Years - 65 Years

Accepts Healthy Volunteers



Jan Stolk, Prof, , 

Location Countries


Location Countries


Administrative Informations



Organization ID

Kamada-AAT (inhaled) 008

Responsible Party


Study Sponsor

Kamada, Ltd.


 Syneos Health

Study Sponsor

Jan Stolk, Prof, Principal Investigator, LUMC

Verification Date

January 2020